Sabzevari Helen 4

What Happened
Helen Sabzevari, President and CEO of Precigen, was granted a total of 1,776,000 equity awards on April 20, 2026: 1,366,000 derivative awards (stock options) and 410,000 restricted stock units (RSUs). The awards are reported at $0.00 per share on the Form 4 (i.e., granted as compensation/derivative awards, not purchases), so the filing shows no cash paid for these items.

Key Details

• Transaction date: April 20, 2026; Form 4 filed April 22, 2026 (within the typical two-business-day Form 4 window).
• Awards reported: 1,366,000 options (derivative) and 410,000 RSUs — total 1,776,000 equity awards. Reported acquisition price: $0.00.
• Shares owned after transaction: not specified in the provided filing details.
• Footnotes from the filing:
  • F1: The options vest 25% on May 23, 2027 and then in equal monthly installments for three years thereafter.
  • F2: Each RSU represents a contingent right to receive one share of Precigen common stock.
  • F3: The RSUs vest 25% on May 23, 2027 and then in equal six‑month installments for three years thereafter.
• Transaction type/code: A = Award/Grant (not a purchase or sale).

Context
These awards are compensation grants subject to multi-year vesting schedules (service/vesting conditions), so they do not represent an immediate purchase of shares or an immediate sale. Options become exercisable over time per the vesting schedule; RSUs convert to shares only as they vest. Such grants are common for executive compensation and do not, by themselves, indicate a buy or sell signal from the insider.